Menu
Recruiting NCT05999214

99mTc-H7ND SPECT/CT Imaging in NSCLC

No phase Interventional NSCLC

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: 99mTc-H7ND SPECT/CT imaging performed.
Who it may be relevant to
Registry conditions: NSCLC. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

99mTc-H7ND SPECT/CT Imaging in Non-small Cell Lung Cancer Clinical Application Research in Efficacy Evaluation and Efficacy Prediction

Overview

To study the clinical application of 99mTc-H7ND SPECT/CT imaging in the efficacy evaluation and prediction of non-small cell lung cancer (NSCLC)

Detailed description

This study was a prospective, controlled, single-center clinical study.

To evaluate the value of 99mTc-H7ND imaging in the evaluation of stable disease in patients with non-small cell lung cancer (NSCLC) assessed by RECIST1.1, and to predict the efficacy of subsequent treatment (second-line treatment).

Patients with NSCLC confirmed by cytology or pathology, who were unable to undergo radical surgery because of recurrence, metastasis, or their own conditions, and who had completed 2-4 cycles of first-line therapy and had RECIST1.1 assessment (SD) were divided into 2 groups:

Experimental group: 99mTc-H7ND SPECT/CT imaging performed Control group: 99mTc-H7ND SPECT/CT imaging was not performed

Interventions

  • Diagnostic test 99mTc-H7ND SPECT/CT imaging performed
    99mTc-H7ND SPECT/CT imaging positive (+) was defined as the presence of at least one measurable lesion and the uptake of the lesion was greater than that of normal liver in the experimental group, and patients were divided into SD+ and SD-. According to the guidelines and routine clinical practice, SD- patients were treated with the original regimen or maintenance treatment, and SD+ patients were divided into continuation of the original regimen or second-line treatment according to the MDT disc

Primary outcome measures

  • DCR [Time frame: Repeat visits were performed 8-12 weeks and 12 weeks after the baseline assessment]
Secondary outcome measures (2)
  • PFS [Time frame: Repeat visits were performed 8-12 weeks and 12 weeks after the baseline assessment]
  • OS [Time frame: Repeat visits were performed 8-12 weeks and 12 weeks after the baseline assessment]

Eligibility criteria

Inclusion criteria

  • Patients aged from 18 to 80 years old;
  • patients with NSCLC confirmed by needle aspiration cytology or surgical pathology, who cannot undergo radical surgery due to recurrence, metastasis or patient's own conditions;
  • Has completed 2-4 cycles of first-line therapy (including chemotherapy, immunotherapy, chemotherapy combined with immunotherapy, chemotherapy combined with targeted therapy, etc.), and has SD assessed by RECIST 1.1 during the same period;
  • Patients had at least one measurable lesion;
  • No local radiotherapy for primary or metastatic lesions within 28 days;
  • ECOG score 0-2;
  • Expected survival time ≥3 months;
  • Voluntarily participate and sign informed consent.

Exclusion criteria

  • Women who plan to become pregnant within 6 months, or are pregnant or lactating.
  • Patients with severe brain or bone metastases;
  • Severe anemia and severe liver and kidney damage;
  • Pathological or long-term follow-up results may not be available;
  • The relevant control imaging data and clinical data were not available;
  • Severe illness is difficult to cooperate (such as acute cardiovascular and cerebrovascular events or serious cardiovascular diseases);
  • Received any surgery or invasive treatment or procedure within 4 weeks before enrollment;
  • Cannot tolerate standard second-line therapy or other first-line therapies.
  • Known allergy to 99mTc-H7ND or any of its components; He had a history of severe allergies;
  • Protocol imaging contraindications were present;
  • The investigator considered it inappropriate to participate in the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Diagnostic

Study locations

China · 1 center
  • First Affiliated Hospital of Xi'an Jiaotong University — Xi'an

Identifiers

NCT: NCT05999214 · XJTU1AF2023LSK-381

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗